Transgene and BioInvent Receive Approval From ANSM to Proceed With Phase I/IIa Trial of Anti-CTLA4-armed Oncolytic Virus BT-001 in Solid Tumors
The Pharma Data
JANUARY 18, 2021
BT-001 is being co-developed through a 50/50 collaboration between Transgene and BioInvent. IN FRANCE, FOUR CLINICAL CENTERS WILL ENROLL PATIENTS. “ We would like to thank the investigators and the clinical teams for their support and look forward to treating the first patients with this first Invir.IO
40 
Let's personalize your content